Pages that link to "Q21558502"
Jump to navigation
Jump to search
The following pages link to Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases (Q21558502):
Displaying 50 items.
- Splice Variants of Androgen Receptor and Prostate Cancer (Q26740592) (← links)
- Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer (Q26858922) (← links)
- Prostate Cancer Stem Cells: Research Advances (Q26998435) (← links)
- Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression (Q27022288) (← links)
- AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer (Q27853062) (← links)
- The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance (Q28076745) (← links)
- Emerging data on androgen receptor splice variants in prostate cancer (Q28077830) (← links)
- Stilbene induced inhibition of androgen receptor dimerization: implications for AR and ARΔLBD-signalling in human prostate cancer cells (Q28539233) (← links)
- Characterization of niphatenones that inhibit androgen receptor N-terminal domain (Q28543404) (← links)
- Registered report: androgen receptor splice variants determine taxane sensitivity in prostate cancer (Q28607383) (← links)
- AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer (Q30544584) (← links)
- TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. (Q30554439) (← links)
- Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases (Q30572057) (← links)
- Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment (Q30573685) (← links)
- Androgen receptor splice variants determine taxane sensitivity in prostate cancer (Q30577613) (← links)
- Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases (Q30596578) (← links)
- The link between androgen receptor splice variants and castration-resistant prostate cancer (Q30618562) (← links)
- Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases (Q30724105) (← links)
- Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. (Q30831010) (← links)
- Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy (Q33688956) (← links)
- The role of mRNA splicing in prostate cancer (Q33922376) (← links)
- Mouse models of prostate cancer: picking the best model for the question. (Q33940867) (← links)
- Differential requirement for Src family tyrosine kinases in the initiation, progression, and metastasis of prostate cancer (Q34364815) (← links)
- Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis (Q34428508) (← links)
- Splicing variants of androgen receptor in prostate cancer. (Q34448143) (← links)
- Beyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting (Q34617627) (← links)
- Methylselenol prodrug enhances MDV3100 efficacy for treatment of castration-resistant prostate cancer (Q34663140) (← links)
- Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes (Q34734595) (← links)
- Constitutive activity of the androgen receptor (Q34775572) (← links)
- Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer (Q34883636) (← links)
- Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer (Q35150756) (← links)
- MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand (Q35238452) (← links)
- N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy (Q35611451) (← links)
- Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy (Q35668319) (← links)
- A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer. (Q35754996) (← links)
- ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. (Q35763908) (← links)
- Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies (Q35842471) (← links)
- Mechanisms of the androgen receptor splicing in prostate cancer cells (Q36005683) (← links)
- Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes (Q36021859) (← links)
- RNA biomarkers to facilitate the identification of aggressive prostate cancer (Q36260364) (← links)
- The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation (Q36294460) (← links)
- Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo. (Q36413805) (← links)
- Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents (Q36414184) (← links)
- Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival (Q36454548) (← links)
- NF-κB and androgen receptor variant expression correlate with human BPH progression (Q36606285) (← links)
- Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression (Q36807948) (← links)
- Role of BioResponse 3,3'-Diindolylmethane in the Treatment of Human Prostate Cancer: Clinical Experience (Q36844904) (← links)
- Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis (Q36961208) (← links)
- Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer (Q36963697) (← links)
- An androgen receptor N-terminal domain antagonist for treating prostate cancer. (Q36966859) (← links)